Other
Standard Dressings
Standard Dressings is an intervention with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_4
1
25%
Ph not_applicable
2
50%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 41 (25.0%)
N/A2 (50.0%)
Trials by Status
completed250%
terminated250%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Efficacy of Negative Pressure Wound Therapy After Total Ankle Arthroplasty
NCT03886818
terminatednot_applicable
Negative Pressure Dressing Therapy in Soft Tissue Sarcoma Surgery
NCT02901405
terminatedphase_4
Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds
NCT00691821
completedphase_1
Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing
NCT00856934
Clinical Trials (4)
Showing 4 of 4 trials
NCT03886818Not Applicable
Efficacy of Negative Pressure Wound Therapy After Total Ankle Arthroplasty
NCT02901405Not Applicable
Negative Pressure Dressing Therapy in Soft Tissue Sarcoma Surgery
NCT00691821Phase 4
Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds
NCT00856934Phase 1
Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing
All 4 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 4